Neúspěšná léčba kombinované mykotické infekce u těžce popáleného pacienta: kazuistika

Autoři: B. Lipový ¹; H. Řihová ¹; M. Hanslianová ¹; P. Brychta ¹
Působiště autorů: Department of Burns and Reconstructive Surgery, University Hospital, Brno, and ¹; Department of Clinical Microbiology, University Hospital, Brno, Czech Republic ²
Vyšlo v časopise: ACTA CHIRURGIAE PLASTICAE, 51, 3-4, 2009, pp. 69-71

Zdroje

1. Maresova V., Urbaskova P. Tigecyklin. Remedia, 18, 2008, p. 194-200.

2. Greer ND. Tigecycline (Tygacil): The first in the glycylcycline class of antibiotics. Proc. Bayl Univ. Med. Cent., 19, 2006, p. 155-161.

3. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of Tigecycline. Clin. Infect. Dis., 41, 2005, p. S333-S340.

4. Pankey GA. Tygecycline. J. Antimicrob. Chemother., 56, 2005, p. 470-480.

5. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infection in hospitalized patients. Clin. Ther., 26(5), 2004, p. 704-714.

6. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J. Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis., 37(8), 2003, p. 997-1005.

7. Frampton JE, Curran MP. Tigecycline. Drugs, 65(18), 2005, p. 2623-2635.

8. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis., 41(10), 2005, p. 1373-1406.

9. Wyeth Pharmaceutics. Tygacil (Tigecycline) for Injection (package insert). Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2005.

10. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. The glycylcyclines: a comparative review with the tetracyclines. Drugs, 64(1), 2004, p. 63-88.

11. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J. Chemother., 17(S1), 2005, p. 12-22.

12. Herndon, DN. Total Burn Care 3rd Edition. Philadelphia: Saunders Elsevier, 2007, p.136-177.

13. Teodorczyk-Injeyan, JA., Sparkes, BG., Mills, GB., Peters, WJ. Immunosuppression follows systemic T lymfocyte activation in the bun patient. Clin. Exp. Immunol., 85(3), 1991, 85(3), p. 515-518.

14. Fraise, AP. Tigecycline: The answer to beta-lactam and fluoroquinolone resistance? J. Infect., 53, 2006, p. 293-300.

15. Vojtova V., Urbánek K. Glycylcykliny –⁠ nová skupiny antibiotik. Klin. Farmakol. Farm., 22(3), 2008, p. 113-115.

16. Dzupova O., Benes J. Tigecycline for treatment of pneumonia. Klin. Mikrobiol. Infekc. Lek., 15, 2009, p. 14-16.